Innovation Delivered
Spatiotemporal in vivo tracking of polyclonal human regulatory T cells (Tregs) reveals a role for innate immune cells in Treg transplant recruitment
Jacinta Jacob1, Suchita Nadkarni2, Alessia Volpe3,6, Qi Peng1, Sim L. Tung1, Rosalind F. Hannen2,
Yasmin R. Mohseni1,3, Cristiano Scotta1, Federica M. Marelli-Berg4, Robert I. Lechler1, Lesley A. Smyth1,5,7, Gilbert O. Fruhwirth3,7, and Giovanna Lombardi1,7
1MRC Centre for Transplantation, Peter Gorer Department of Immunobiology, School of Immunology and Microbial Science, King’s College London, Guy’s Hospital, London SE1 9RT, UK;
2Centre for Cell Biology & Cutaneous Research, The Blizard Institute, Bart’s and The London School of Medicine and Dentistry, Queen Mary University of London, London E1 2AT, UK;
3Imaging Therapies and Cancer Group, School of Biomedical Engineering and Imaging Sciences, King’s College London, London SE1 7EH, UK;
4William Harvey Research Institute, Bart’s and The London School of Medicine, Queen Mary University of London, London EC1M 6BQ, UK;
5School of Health, Sport and Bioscience, Stratford Campus, University of East London, London E16 2RD, UK
6Present address: Molecular Imaging Group, Department of Radiology, Memorial Sloan Kettering Cancer Center, 417 E 68th St., New York, NY 10065, USA
7Senior author
https://doi.org/10.1016/j.omtm.2020.12.003
Summary
Regulatory T cells (Tregs) have gained important role in mechanisms of transplantation tolerance and graft survival due to their putative capability to control immune responses. They can prolong the survival of allografts when they are administered after their purification from blood and further manipulated in vitro.
Despite an increase in the number of clinical trials using Treg therapy, important questions remain unclear such as their in vivo biodistribution over couple of weeks.
The aim of the present study was to investigate their long-term (for up to 40 days) biodistribution in vivo by SPECT imaging in mice bearing human skin transplants. As long-term tracking is challenging if radioactive dose has to be minimized, transplanted mice received genetically modified human Treg cells: they were lentivirally transduced with the human sodium iodide symporter (hNIS) and for the imaging, its alternative substrate, pertechnetate (99mTcO4¯) was injected iv. on the days of the scan. In one group of mice Gr-1+ cells (including neutrophils and certain monocytes) were depleted using an antibody raised against Gr-1 to achieve a high level of immunocompromise.
Results show that 99mTcO4¯ uptake was elevated much earlier in the presence of Gr-1+ cells, suggesting their active, accelerating role in influencing Treg recruitment to the graft.
Results from nanoScan SPECT/CT
Skin grafts were transplanted onto 10-12-week-old recipient BRG or NSG mice. 5–6 week later, 5x106 peripheral blood mononuclear cells (PBMCs) were then administered iv. with or without 5x106 Tregs. Some BRG mice received 100mg anti-mouse Gr-1 ip. every two days.
For SPECT/CT imaging 20 MBq 99mTcO4¯ was administered iv. and SPECT scans were acquired 40 min later with nanoScan SPECT/CT. Data were reconstructed using Tera-Tomo with corrections for attenuation, detector dead time, and radioisotope decay in place as needed. CT images were used to draw ROIs and provide the volumes required for standard uptake value calculations. The total activity in the whole animal (excluding the tail) at the time of tracer administration was defined as the injected dose (ID).
- Serial SPECT/CT imaging of mice received Cr-1 antibody revealed that radiotracer uptake in the human skin grafts did not differ from control animals in the first 2 weeks, but at late time points (ranging 30–40 days after administration) Treg presence was significantly elevated.
- In case of the presence of Gr-1+ cells, Tregs were detectable at the skin grafts as early as 3 days after administration. Their signals peaked at around 8 days and remained detectable in the transplants up to 40 days after administration. Early trafficking of Tregs to the skin in the presence of Gr-1+ cells suggested an active, accelerating role of these cells in influencing Treg recruitment to the graft.
